BC Week In Review | Jul 20, 2009
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif.   Business: Autoimmune, Neurology   Hired: Paulette Dillon as CBO, formerly CBO at Anacor Pharmaceuticals Inc. ; and Tito Serafini as CSO, formerly VP at Renovis Inc. (now part...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
BioCentury | Jun 8, 2009
Finance

Managing Austerity

In its first review of European biotech finance in 1999, BioCentury noted that the industry faced the potential dilemma of having too many clinical programs and not enough capital to finance their development. The first...
BC Week In Review | May 11, 2009
Company News

Evotec neurology news

Evotec will restructure and reduce headcount for the second time in two months, restructuring its drug discovery and development operations and cutting headcount by about 45 (12%) to less than 330 to save cash. The...
BC Week In Review | Aug 11, 2008
Clinical News

VRI antagonist: Phase I started

Pfizer began a double-blind, placebo-controlled, single ascending-dose Phase I trial in healthy volunteers with an oral VR1 antagonist . Pfizer and Renovis Inc. , which was recently acquired by Evotec, combined their small molecule VR1 antagonist programs...
BioCentury | Jun 30, 2008
Strategy

Pfizer fleshing out its model

Since announcing the Biotherapeutics and Bioinnovation Center in October last year, Pfizer Inc. has begun to string together deals it anticipates will provide proof-of-principle for a model it hopes will successfully marry the nimbleness and...
BC Innovations | May 22, 2008
Targets & Mechanisms

So FAAH, So Good, Maybe

A paper in Nature Chemical Biology describes the potent analgesic effect of a class of organophosphorus compounds that enhances cannabinoid receptor activity. 1 Unlike pain treatments based on agonizing cannabinoid receptors with compounds such as...
BC Week In Review | May 12, 2008
Company News

Evotec, Renovis deal

Evotec completed its previously announced acquisition of Renovis for about 35 million shares valued at E58.8 million ($90.6 million) based on Evotec’s close of E1.68 on May 2, the last trading day before the deal...
BioCentury | May 12, 2008
Finance

Ebb & Flow

Rumors that GPC Biotech (Xetra:GPC; NASDAQ:GPCB) may merge with Wilex (FSE:WL6) triggered a major rally for GPC last week. Fueled by newspaper reports on Wednesday, GPC gained E1.53 (83%) to E3.38 on Xetra and $1.66...
BioCentury | Mar 24, 2008
Product Development

Neurocognitive mind-field

The difficulties inherent in developing therapeutic agents for neurocog-nitive disorders have been well documented, as the complexity of brain dysfunction does not lend itself to successful intervention by a single pharmaceutical agent. Nor are the...
Items per page:
1 - 10 of 152
BC Week In Review | Jul 20, 2009
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif.   Business: Autoimmune, Neurology   Hired: Paulette Dillon as CBO, formerly CBO at Anacor Pharmaceuticals Inc. ; and Tito Serafini as CSO, formerly VP at Renovis Inc. (now part...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
BioCentury | Jun 8, 2009
Finance

Managing Austerity

In its first review of European biotech finance in 1999, BioCentury noted that the industry faced the potential dilemma of having too many clinical programs and not enough capital to finance their development. The first...
BC Week In Review | May 11, 2009
Company News

Evotec neurology news

Evotec will restructure and reduce headcount for the second time in two months, restructuring its drug discovery and development operations and cutting headcount by about 45 (12%) to less than 330 to save cash. The...
BC Week In Review | Aug 11, 2008
Clinical News

VRI antagonist: Phase I started

Pfizer began a double-blind, placebo-controlled, single ascending-dose Phase I trial in healthy volunteers with an oral VR1 antagonist . Pfizer and Renovis Inc. , which was recently acquired by Evotec, combined their small molecule VR1 antagonist programs...
BioCentury | Jun 30, 2008
Strategy

Pfizer fleshing out its model

Since announcing the Biotherapeutics and Bioinnovation Center in October last year, Pfizer Inc. has begun to string together deals it anticipates will provide proof-of-principle for a model it hopes will successfully marry the nimbleness and...
BC Innovations | May 22, 2008
Targets & Mechanisms

So FAAH, So Good, Maybe

A paper in Nature Chemical Biology describes the potent analgesic effect of a class of organophosphorus compounds that enhances cannabinoid receptor activity. 1 Unlike pain treatments based on agonizing cannabinoid receptors with compounds such as...
BC Week In Review | May 12, 2008
Company News

Evotec, Renovis deal

Evotec completed its previously announced acquisition of Renovis for about 35 million shares valued at E58.8 million ($90.6 million) based on Evotec’s close of E1.68 on May 2, the last trading day before the deal...
BioCentury | May 12, 2008
Finance

Ebb & Flow

Rumors that GPC Biotech (Xetra:GPC; NASDAQ:GPCB) may merge with Wilex (FSE:WL6) triggered a major rally for GPC last week. Fueled by newspaper reports on Wednesday, GPC gained E1.53 (83%) to E3.38 on Xetra and $1.66...
BioCentury | Mar 24, 2008
Product Development

Neurocognitive mind-field

The difficulties inherent in developing therapeutic agents for neurocog-nitive disorders have been well documented, as the complexity of brain dysfunction does not lend itself to successful intervention by a single pharmaceutical agent. Nor are the...
Items per page:
1 - 10 of 152